Alkem Laboratories Limited, an Indian multinational pharmaceutical company, has signed a license agreement with Harvard University's Office of Technology Development enabling Alkem to develop and commercialize a novel technology that may help meet the dire need for effective treatment of diabetic neuropathy, foot ulcers, peripheral arterial disease (PAD), and other injuries caused by vascular disease.